Lung Cancer Trial, Recruiting NCT06634979 Sponsor: Fudan University Condition: Lung Cancer
Back to Lung Cancer

Lung Cancer Trial, Recruiting

NCT06634979
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who are willing to take part in a clinical study and are able to follow and complete all study procedures
  • People aged between 18 and 80 years old at the time of signing the consent form (including those who are exactly 18 or 80)
  • People with a good general health and activity level, rated as fully active or able to carry out light work (ECOG score of 0 or 1)
  • People who have not previously had surgery for lung cancer
  • People whose lung cancer type has been confirmed during or after surgery as non-small cell lung cancer
  • People who have a single lung nodule that appears as a mix of solid and hazy (ground glass) areas on a CT scan, or multiple nodules where the main nodule matches this description
  • People whose nodule has a solid portion making up between 50% and 100% of the nodule, and where the total nodule size is 2 cm or smaller
  • People whose cancer is at an early stage (T1N0M0) and where surgery to fully remove the cancer is considered possible
  • People who have not yet received any radiotherapy or chemotherapy as an initial treatment

Who may not be able to join:

  • People whose cancer does not meet the specific early-stage criteria of a solid portion between 50% and 100% with a diameter of 2 cm or less (confirm with trial site)
  • People for whom complete surgical removal of the cancer is not possible
  • People whose cancer has been confirmed by tissue or cell testing to be a type of lung cancer other than non-small cell lung cancer
  • People who have previously had surgery for lung cancer
  • People who have already received radiotherapy or chemotherapy, where that treatment was not the first (primary) treatment given

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 22 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Haiquan Chen, Fudan University

Phone: +86-13278979834

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Registry
ClinicalTrials.gov
Start date
1 May 2024
Est. completion
1 May 2026

Where this trial is recruiting

🇨🇳 China

Primary endpoints

2-year disease-free survival

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 22 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov